Close Menu

NEW YORK (GenomeWeb) – Amoy Diagnostics, Premia Holdings, and Loxo Oncology today announced a partnership aimed at genetic screening of patients for a targeted cancer therapy.

As part of the deal, China-based AmoyDx and Tokyo-headquartered Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development. AmoyDx's multigene PCR and next-generation sequencing panels will be used to identify patients with RET genetic alteration.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.